| Bioactivity | BMD4503-1 is a quinoxaline derivative. BMD4503-1 can inhibit the LRP5/6-Sclerostin interaction and regulate the Wnt signaling pathway[1]. |
| CAS | 301357-76-6 |
| Formula | C22H19N5O3S |
| Molar Mass | 433.48 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Choi J, et al. In silico discovery of quinoxaline derivatives as novel LRP5/6-sclerostin interaction inhibitors. Bioorg Med Chem Lett. 2018 Apr 1;28(6):1116-1121. |
BMD4503-1
CAS: 301357-76-6 F: C22H19N5O3S W: 433.48
BMD4503-1 is a quinoxaline derivative. BMD4503-1 can inhibit the LRP5/6-Sclerostin interaction and regulate the Wnt sign
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.